The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
118244946 11824494 6 F 2010 20160809 20151210 20160817 EXP GB-MYLANLABS-2015M1043054 MYLAN 0.00 Y 0.00000 20160817 OT GB GB

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
118244946 11824494 1 PS AMLODIPINE AMLODIPINE BESYLATE 1 Unknown UNK U U 76418
118244946 11824494 2 SS HERCEPTIN TRASTUZUMAB 1 Subcutaneous 450 MG, UNK U U B1010B08,B00442B01, B104B13 0 450 MG
118244946 11824494 3 SS HERCEPTIN TRASTUZUMAB 1 600 UNK, UNK U U B1010B08,B00442B01,B104B13 0 600 MG

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
118244946 11824494 1 Product used for unknown indication
118244946 11824494 2 Product used for unknown indication

Outcome of event

Event ID CASEID OUTC COD
118244946 11824494 OT

Reactions reported

Event ID CASEID DRUG REC ACT PT
118244946 11824494 Arthralgia
118244946 11824494 Bladder irritation
118244946 11824494 Blood pressure increased
118244946 11824494 Dizziness
118244946 11824494 Dry skin
118244946 11824494 Dysuria
118244946 11824494 Fall
118244946 11824494 Fatigue
118244946 11824494 Feeling abnormal
118244946 11824494 Gingival pain
118244946 11824494 Head injury
118244946 11824494 Hepatic neoplasm
118244946 11824494 Joint swelling
118244946 11824494 Lacrimation increased
118244946 11824494 Local swelling
118244946 11824494 Musculoskeletal stiffness
118244946 11824494 Myalgia
118244946 11824494 Nasal congestion
118244946 11824494 Neoplasm progression
118244946 11824494 Neuralgia
118244946 11824494 Onychoclasis
118244946 11824494 Pain in extremity
118244946 11824494 Photophobia
118244946 11824494 Pruritus
118244946 11824494 Rhinorrhoea
118244946 11824494 Sinus pain
118244946 11824494 Skin abrasion
118244946 11824494 Trigeminal neuralgia
118244946 11824494 Urinary retention
118244946 11824494 Urine flow decreased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

no results found